Валеология: Здоровье, Болезнь, Выздоровление. 2020; : 76-81
К ВОПРОСУ О КАРДИОТОКСИЧНОСТИ ХИМИОТЕРАПИИ
Аннотация
Старение населения мира увеличивает частоту заболевания раком и болезнями сердечно-сосудистой системы (ССС). Онкологическое заболевание, а также методы его лечения повышают вероятность развития тяжелых кардиальных осложнений. Вниманию читателей предлагается обзор литературы по вопросам кардиотоксичности различных групп химиопрепаратов.
Список литературы
1. Cancer Data and Statistics. 2011. http://www.cdc.gov/cancer/dcpc/data/ Accessed on 10 June 2015.
2. Hermann J., Lerman A. An update on cardiooncology // Trends Cardiovasc Med. - 2014. - № 24. - Р. 285-295.
3. Zamorano J. L., et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology // Eur Heart J.- 2016. - Sep 21.- № 37 (36) . - Р. 2768-2801.
4. Iliescu C., et al. SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catheterization Laboratory // Catheter Cardiovasc Interv. - 2016. - Apr. - № 87 (5). - Р. 202-23.
5. Plana JC, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J Am Soc Echocardiog. - 2014. - № 27. - Р. 911-39.
6. Чазова И. Е. Руководство по диагностике, профилактике и лечению сердечно-сосудистых осложнений противоопухолевой терапии / И. Е. Чазова [и др.] // Системные гипертензии. - 2018. -№ 15. - С. 6–20.
7. Romond E. H., Jeong J.-H., Rastogi P. et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with nodepositive, human epidermal growth factor receptor 2-positive breast cance // J Clin Oncol. - 2012.-№ 30. - Р. 3792–9.
8. Chow E. J., Baker K. S., Lee S. J. et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation // J Clin Oncol. - 2014. - № 32. - Р. 191–8.
9. Armenian S. H., Xu L., Ky B. et al. Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study // J Clin Oncol. - 2016. - № 34. - Р. 1122–30.
10. Farolfi A., Melegari E., Aquilina M. et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factor // Heart.- 2013. - № 99. - Р. 634–9.
11. Perez E. A., Romond E. H., Suman V. J., Jeong J. H., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-3 // J Clin Oncol. - 2011. - № 29. - Р. 3366–3373.
12. Bang Y. J., Van Cutsem E., Feyereislova A., Chung H. C., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial // Lancet . - 2010. - № 376. - Р. 687-697.
13. Gianni M., Dentali F., Lonn E. 5 flourouracilinduced apical ballooning syndro-me: A case report // Blood Coagul Fibrinolysis. - 2009. - № 20. - Р. 306-308.
14. Polk A., Vaage-Nilsen M., Vistisen K., Nielsen D. L. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors // Cancer Treat Rev. - 2013 Dec. - № 39 (8). - Р. 974-84.
15. Ambrosy A. P., Kunz P. L., Fisher G. A., Witteles R. M. Capecitabine induced chest pain relieved by diltiazem // Am J Cardio. - 2012. - № 110. - Р. 1623-1626.
16. Karabay K. O., Yildiz O., Aytekin V. Multiple coronary thrombi with cisplatiт // J Invasive Cardiol. - 2014. - № 26. - Р. 18-20.
17. Schutz F. A., Je Y,. Azzi G. R., Nguyen P. L., Choueiri T. K. Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes // Ann Oncol. - 2011; №22. - Р. 1404-1412.
18. Sen F., Yildiz I., Basaran M., et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitini // J Buon. - 2013. - № 18. - Р. 775-781.
19. Porto I., Leo A., Miele L., et al. A case of variant angina in a patient under chronic treatment with sorafenib // Nat Rev Clin Oncol. - 2010. - № 7. - Р. 476-480.
20. Naib T., Steingart R. M., Chen C. L. Sorafenibassociated multivessel coronary artery vasospasm // Herz. - 2011. - № 36. - Р. 348-351.
21. Holm P. W., Slart R. H., Zeebregts C. J., Hillebrands J. L., Tio R. A. Atherosclerotic plaque development and instability: A dual role for VEGF // Ann Med. - 2009. - № 41. - Р. 257- 264.
22. Quintas-Cardama A., Kantarjian H., Cortes J. Nilotinib-associated vascular events // Clin Lymphoma Myeloma Leuk. - 2012. - № 12. - Р. 337-340.
23. Arunprasath P., Gobu P., Dubashi B., Satheesh S., Balachander J. Rituximab induced myocardial infarction: A fatal drug reaction // J Cancer Res Ther. - 2011. - № 7. - Р. 346-348.
24. Togna G. I., Togna A. R., Franconi M., Caprino L. Cisplatin triggers platelet activation // Thromb Res. - 2000. - № 99. - Р. 503-509.
25. Dieckmann K. P., Gerl A., Witt J., Hartmann J. T. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer // Ann Onco. - 2010. - № 21. - Р. 1607-1611.
26. van Werkum J. W., Heestermans A. A., Zomer A. C., et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry // J Am Coll Cardio. - 2009. - № 53. - Р. 1399-1409.
27. Cahill T. J., Chowdhury O., Myerson S. G., et al. Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: Diagnosis and follow-up by cardiac magnetic resonance imaging // Circulation. - 2011. - № 123. - Р. 370-375.
28. Plana J. C., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J Am SocEchocardiogr. - 2014. - № 27. - Р. 911–39.
29. Curigliano G., Cardinale D., Suter T. et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines // Ann Oncol. - 2012; № 23 (Suppl. 7) . - Р. 155–166.
30. Curigliano G., Cardinale D., Dent S. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management // CA Cancer J Clin. - 2016. - № 66. - Р. 309–25.
Valeology: Health - Illnes - recovery. 2020; : 76-81
TO THE QUESTION OF CHEMOTHERAPY CARDIOTOXICITY
Abstract
An aging world population is increasing the incidence of cancer and diseases of the cardiovascular system (CVS). An oncological disease, as well as methods of its treatment, increase the probability of developing severe cardiac complications. For consideration of readers is offered review of the literature about cardiotoxicity of various groups of chemotherapy drugs.
References
1. Cancer Data and Statistics. 2011. http://www.cdc.gov/cancer/dcpc/data/ Accessed on 10 June 2015.
2. Hermann J., Lerman A. An update on cardiooncology // Trends Cardiovasc Med. - 2014. - № 24. - R. 285-295.
3. Zamorano J. L., et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology // Eur Heart J.- 2016. - Sep 21.- № 37 (36) . - R. 2768-2801.
4. Iliescu C., et al. SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catheterization Laboratory // Catheter Cardiovasc Interv. - 2016. - Apr. - № 87 (5). - R. 202-23.
5. Plana JC, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J Am Soc Echocardiog. - 2014. - № 27. - R. 911-39.
6. Chazova I. E. Rukovodstvo po diagnostike, profilaktike i lecheniyu serdechno-sosudistykh oslozhnenii protivoopukholevoi terapii / I. E. Chazova [i dr.] // Sistemnye gipertenzii. - 2018. -№ 15. - S. 6–20.
7. Romond E. H., Jeong J.-H., Rastogi P. et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with nodepositive, human epidermal growth factor receptor 2-positive breast cance // J Clin Oncol. - 2012.-№ 30. - R. 3792–9.
8. Chow E. J., Baker K. S., Lee S. J. et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation // J Clin Oncol. - 2014. - № 32. - R. 191–8.
9. Armenian S. H., Xu L., Ky B. et al. Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study // J Clin Oncol. - 2016. - № 34. - R. 1122–30.
10. Farolfi A., Melegari E., Aquilina M. et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factor // Heart.- 2013. - № 99. - R. 634–9.
11. Perez E. A., Romond E. H., Suman V. J., Jeong J. H., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-3 // J Clin Oncol. - 2011. - № 29. - R. 3366–3373.
12. Bang Y. J., Van Cutsem E., Feyereislova A., Chung H. C., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial // Lancet . - 2010. - № 376. - R. 687-697.
13. Gianni M., Dentali F., Lonn E. 5 flourouracilinduced apical ballooning syndro-me: A case report // Blood Coagul Fibrinolysis. - 2009. - № 20. - R. 306-308.
14. Polk A., Vaage-Nilsen M., Vistisen K., Nielsen D. L. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors // Cancer Treat Rev. - 2013 Dec. - № 39 (8). - R. 974-84.
15. Ambrosy A. P., Kunz P. L., Fisher G. A., Witteles R. M. Capecitabine induced chest pain relieved by diltiazem // Am J Cardio. - 2012. - № 110. - R. 1623-1626.
16. Karabay K. O., Yildiz O., Aytekin V. Multiple coronary thrombi with cisplatit // J Invasive Cardiol. - 2014. - № 26. - R. 18-20.
17. Schutz F. A., Je Y,. Azzi G. R., Nguyen P. L., Choueiri T. K. Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes // Ann Oncol. - 2011; №22. - R. 1404-1412.
18. Sen F., Yildiz I., Basaran M., et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitini // J Buon. - 2013. - № 18. - R. 775-781.
19. Porto I., Leo A., Miele L., et al. A case of variant angina in a patient under chronic treatment with sorafenib // Nat Rev Clin Oncol. - 2010. - № 7. - R. 476-480.
20. Naib T., Steingart R. M., Chen C. L. Sorafenibassociated multivessel coronary artery vasospasm // Herz. - 2011. - № 36. - R. 348-351.
21. Holm P. W., Slart R. H., Zeebregts C. J., Hillebrands J. L., Tio R. A. Atherosclerotic plaque development and instability: A dual role for VEGF // Ann Med. - 2009. - № 41. - R. 257- 264.
22. Quintas-Cardama A., Kantarjian H., Cortes J. Nilotinib-associated vascular events // Clin Lymphoma Myeloma Leuk. - 2012. - № 12. - R. 337-340.
23. Arunprasath P., Gobu P., Dubashi B., Satheesh S., Balachander J. Rituximab induced myocardial infarction: A fatal drug reaction // J Cancer Res Ther. - 2011. - № 7. - R. 346-348.
24. Togna G. I., Togna A. R., Franconi M., Caprino L. Cisplatin triggers platelet activation // Thromb Res. - 2000. - № 99. - R. 503-509.
25. Dieckmann K. P., Gerl A., Witt J., Hartmann J. T. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer // Ann Onco. - 2010. - № 21. - R. 1607-1611.
26. van Werkum J. W., Heestermans A. A., Zomer A. C., et al. Predictors of coronary stent thrombosis: The Dutch Stent Thrombosis Registry // J Am Coll Cardio. - 2009. - № 53. - R. 1399-1409.
27. Cahill T. J., Chowdhury O., Myerson S. G., et al. Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: Diagnosis and follow-up by cardiac magnetic resonance imaging // Circulation. - 2011. - № 123. - R. 370-375.
28. Plana J. C., Galderisi M., Barac A. et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // J Am SocEchocardiogr. - 2014. - № 27. - R. 911–39.
29. Curigliano G., Cardinale D., Suter T. et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines // Ann Oncol. - 2012; № 23 (Suppl. 7) . - R. 155–166.
30. Curigliano G., Cardinale D., Dent S. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management // CA Cancer J Clin. - 2016. - № 66. - R. 309–25.
